Zhaoyang Teng
Council Member
Dr. Zhaoyang Teng, Senior Director of Biostatistics,
currently leads the Medical Affairs Statistical Science team
at Astellas. He brings extensive expertise across all phases
of drug development (Phases I–III) and post-marketing
activities, including global regulatory and HTA submissions,
HEOR, market access, and global medical affairs.
Before joining Astellas, Dr. Teng served as Senior Director
of Biostatistics at Servier, where he led the LCM
Biostatistics team for oncology—covering HEOR, Market
Access, GMPA, and RWE analytics—as well as the APAC
Biostatistics team based in Beijing, China. He also held
positions at Takeda Pharmaceuticals earlier in his career.
Dr. Teng earned his PhD in Biostatistics from Boston
University. His research interests include adaptive and
seamless Phase 2/3 study designs, biomarker-driven designs,
model-based meta-analysis, multi-regional clinical trials,
enrollment prediction, indirect treatment comparisons (ITC),
quantitative benefit-risk analysis, and the application of
AI in drug development.
He is an active member of several professional statistical
communities, including ASA, BCASA, NESS, ICSA, Stat4Onc,
SIP, NERDS and DISS, contributing to the advancement of the
field and organizing local and global events.
